Introdução: a colonização de indivíduos com HIV/aids por microrganismos patogênicos tem sido associada a maior risco de morbidade e mortalidade, principalmente quando esse microrganismo é o Staphylococcus aureus. Identificar precocemente esta condição permite implementar medidas preventivas do adoecimento a ele relacionado, em nível individual e coletivo. Objetivo: avaliar a prevalência de colonização por Staphylococcus aureus em indivíduos com HIV/aids internados em um hospital escola. Metodologia: estudo de corte transversal, tendo como sujeito pessoas vivendo com HIV/aids, internadas em duas unidades especializadas em HIV/aids de um Hospital Escola do município de Ribeirão Preto- SP. Todos os preceitos éticos foram criteriosamente respeitados. No período de Agosto/2011 a Julho/2012, todos os indivíduos internados foram abordados e para aqueles que aceitaram participar, procedeu-se a coleta de amostra de saliva e secreção nasal, além da coleta de dados sociodemográficos, clínicos e imunológicos, obtidos por meio do prontuário e entrevista individual. As amostras foram encaminhadas e processadas pelo Laboratório de Microbiologia e Sorologia da instituição em estudo. Foram semeadas em meios de cultura ágar sangue e manitol, e após, transferidas para o sistema automatizado Vitek® 2 (BioMérieux(TM)), por meio dos cartões GP Test Kit Vitek® 2, para bactérias gram-positivas. Foram empregados cartões AST-P585 para avaliar a sensibilidade dos Staphylococcus aureus meticilina resistente (MRSA) aos antibióticos. Os dados foram armazenados em planilhas do Microsoft Office Excel 2011 for Mac e organizados por meio do software Statistical Package for the Social Sciences (SPSS), versão 17.0 for Windows. Resultados: De 229 indivíduos com HIV/aids internados nas unidades, 169 constituíram os sujeitos desta pesquisa, dos quais 57,4% eram do sexo masculino, 39,6% apresentaram idade de 40 a 49 anos e 45% tinham o primeiro grau completo. Foram obtidas 338 amostras (169 de secreção nasal e 169 de saliva). A prevalência de colonização por Staphylococcus aureus foi identificada em 20,4% das amostras, com 21,7% de resistência à oxacilina, sendo em secreção nasal 66,7% e em saliva 33,3%. Apresentaram contagem de linfócitos T CD4 abaixo de 200 células/mm3 60,0% dos indivíduos com MRSA nasal e 80,0% estavam em uso de antimicrobianos. Em 40,0% dos indivíduos com MRSA na saliva carga viral foi igual ou superior a 500.001 cópias/mL, e 80,0% destes também usavam antimicrobianos, MRSA nasal e saliva foi identificado em 60,0% dos indivíduos que não estavam em uso de antirretroviral. Conclusão: a prevalência de colonização por Staphylococcus aureus em indivíduos com HIV/aids foi predominante em secreção nasal, com baixa contagem de linfócitos T CD4, com história de internação prévia, uso de antimicrobiano e ausência do uso de antirretroviral, podendo representar importante fonte de infecção. / Introduction: colonization by pathogenic microorganisms in individuals with HIV/AIDS has been associated with increased risk of morbidity and mortality, especially when that organism is Staphylococcus aureus. Early identification of this condition allows implementing preventive measures of illness related to it, both individually and collectively. Objective: to evaluate the prevalence of Staphylococcus aureus colonization in individuals with HIV/AIDS in a teaching hospital. Method: cross-sectional study; the subjects were people living with HIV/AIDS and hospitalized in two specialized HIV/AIDS care units of a Teaching Hospital in the city of Ribeirão Preto. All ethical principles were carefully observed. In the period from August 2011 to July 2012, all subjects hospitalized were approached and, for those who agreed to participate, the collection of saliva and nasal discharge sample was performed, in addition to collecting sociodemographic, clinical and immunological data, obtained through medical record and individual interviews. The samples were forwarded and processed by the Laboratory of Microbiology and Sorology of the institution. They were seeded in blood agar and mannitol-salt-agar culture medium, and thereafter, transferred to the automated system Vitek® 2 (BioMérieux(TM)) through Vitek® 2 Test Cards for Gram-positive bacteria. AST-P585 cards were used to assess the sensitivity of methicillin-resistant Staphylococcus aureus (MRSA) to the antibiotic. Data were stored in spreadsheets of Microsoft Office Excel 2011 for Mac and organized by the Statistical Package for the Social Sciences (SPSS) version 17.0 for Windows. Results: of the 229 individuals with HIV/AIDS hospitalized in the units, 169 were the subjects in this study, of whom 57.4% were male, 39.6% were aged from 40 to 49 years, and 45% had completed elementary school. 338 samples were collected (169 of nasal discharge and 169 of saliva). The prevalence of Staphylococcus aureus colonization was identified in 20.4% of samples, with 21.7% of oxacillin resistance, being 66.7% in nasal discharge and 33.3% in saliva. 60.0% of individuals with MRSA in nasal had lymphocytes T CD4 count below 200 cells/mm3 , and 80.0% were taking antimicrobials. In 40.0% of the individuals with MRSA in saliva, the viral load was equal or higher than 500.001 copies/mL, and 80.0% of these also used antimicrobials; MRSA in nasal and in saliva were detected in 60.0% of individuals who were not taking antiretroviral. Conclusion: the prevalence of Staphylococcus aureus colonization in individuals with HIV/AIDS was prevalent in nasal discharge, had lymphocytes T CD4 low count, with a history of previous hospitalization, antimicrobial use and the absence of antiretroviral use, and it may represent an important source of infection.

Vancomycin is one of the most extensively used antibacterial agents for the treatment of severe gram positive infections including methicillin-resistant Staphylococcus aureus. It is also known that the use of this antimicrobial is a risk factor for subsequent colonization or infection with vancomycin-resistant Enterococcus (VRE). This retrospective observational study was to evaluate the results of vancocinemias that were conducted in adult and pediatric patients hospitalized in the period january to november 2012 at the University Hospital of Santa Maria (HUSM). Were evaluated 353 vancocinemias performed in 115 patients. Of the total, 180 vancocinemias were collected in the TROUGH, of these 150 (83.33%) were above the recommended range, 20 (11.11%) were within the expected values and 10 (5.56%) showed lower than expected. The review was carried out in 26 patients at the PEAK, 15 (57.69%) showed lower serum concentrations recommended, 5 (19.23%) were within the range and 6 (23.08%) had values greater than those expected. The remaining 147 (41.64%), was not collected in strips of PEAK and TROUGH. These data confirm the importance and necessity of conducting a routine therapeutic monitoring of vancomycin, through the creation and implementation of a collection routine. / A vancomicina constitui-se em um dos agentes antibacterianos mais extensivamente utilizados para o tratamento de infecções severas de patógenos gram positivos envolvendo Staphylococcus aureus resistentes à meticilina. Sabe-se também que o uso desse antimicrobiano constitui fator de risco para subsequente colonização ou infecção por Enterococcus resistentes à vancomicina (VRE). Esse estudo observacional retrospectivo teve como objetivo avaliar os resultados das vancocinemias que foram realizadas nos pacientes adultos e pediátricos internados no período de janeiro a novembro de 2012 no Hospital Universitário de Santa Maria (HUSM). Foram avaliadas 353 vancocinemias realizadas em 115 pacientes. Do total, 180 (50,99%) vancocinemias foram coletadas no VALE, destas 150 (83,33%) estavam acima da faixa recomendada, 20 (11,11%) estavam dentro dos valores esperados e 10 (5,56%) apresentaram valores abaixo do esperado. O exame foi realizado em 26 (7,37%) pacientes no PICO, sendo que 15 (57,69%) apresentaram valores inferiores às concentrações séricas recomendadas, 5 (19,23%) encontravam-se dentro da faixa e 6 (23,08%) tiveram valores superiores aos esperados. O restante, 147 (41,64%), não foi coletado em faixas de PICO e VALE. Estes dados confirmam a importância e a necessidade da realização de uma rotina de monitoramento terapêutico da vancomicina, através da criação e implementação de uma de rotina de coleta.

Vancomicina é o antimicrobiano de escolha no tratamento de bacteremias causadas por estafilococos resistentes à meticilina. No entanto, estudos recentes têm reportado que a vancomicina apresenta atividade reduzida contra Staphylococcus aureus resistentes à meticilina com concentrações inibitórias mínimas (CIMs) próximas do limite do ponto de corte de suscetibilidade, conforme critérios do CLSI, indicando falha terapêutica. Entretanto, existem poucos estudos à respeito dos Staphylococcus sp. coagulase negativa resistentes à meticilina (SCoNRM). Ademais, para determinação da CIM, deveria ser utilizado o método de referência microdiluição em caldo (MDC), mas a maioria dos laboratórios clínicos utiliza a técnica de Etest ou sistemas automatizados. Alguns estudos com S. aureus demonstraram discrepâncias entre MDC e Etest, contudo não existem dados referentes aos SCoN. Os objetivos deste estudo foram avaliar a correlação entre as CIMs de vancomicina determinadas pelas técnicas de MDC e Etest em 130 SCoNRM isolados de hemocultura, bem como verificar a relação entre valores de CIM e falha terapêutica entre pacientes com bacteremia por SCoNRM tratados com este antimicrobiano. A maioria dos resultados de CIM por MDC (98,5%) foram ≤1,0 mg/mL, enquanto o Etest apresentou 72,3% de CIM ≥ 1,5 mg/mL. As CIMs de vancomicina obtidas por Etest foram, em geral, uma a duas diluições maiores do que as CIMs obtidas por MDC. Os resultados indicam que a técnica de Etest gera valores de CIM consistentemente maiores do que os obtidos por MDC nos SCoNRM. Apenas 37 (28,5%) dos 130 pacientes com hemocultura positiva para SCoNRM apresentaram dados clínicos compatíveis com bacteremia. A maioria dos pacientes com bacteremia comprovada (n=24) apresentaram CIMs de vancomicina ≥1,5 mg/mL, sendo que 13 pacientes (35,1%) obtiveram CIM < 1,5 mg/mL. Este estudo não observou relação estatisticamente significativa entre valores de CIM de vancomicina que pudessem ser associados com falha terapêutica em pacientes com bacteremia por SCoNRM. / Vancomycin is the first-line therapy for methicillin-resistant staphylococci bacteremia. However, recent studies have reported that vancomycin demonstrates reduced activity against methicillin-resistant Staphylococcus aureus bacteremia, with vancomycin MICs at the high end of the CLSI susceptibility range indicating treatment failure. There is, however, little data considering methicillin-resistant coagulase-negative staphylococci (MRCoNS) bacteremia. Besides, the reference method that should be used for MIC determination is the broth microdilution (BMD), but many clinical laboratories use the commercial Etest technique or automated systems. Some reports have showed a growing number of vancomycin MIC discrepancies between BMD and Etest method for S. aureus, but there are no studies about CoNS. The aims of this study were to evaluated the correlation between the vancomycin MIC determined by the Etest and the BMD method for a total of 130 MRCoNS bloodstream isolates as well as to examine the relationship between vancomycin MICs and failure among patients with MRCoNS bacteremia treated with vancomycin. The vast majority (98.5%) of MIC results by BMD were ≤1.0 mg/mL in contrast to MIC by Etest which majority (72.3%) was ≥1.5 mg/mL. The vancomycin MICs obtained by the Etest for the same isolates were, in general, one to twofold higher than those obtained by the BMD method. The results indicate that the Etest provides vancomycin MIC values consistently higher than those obtained by BMD method for MRCoNS. Only 37 (28.5%) out of the 130 patients with a positive MRCoNS bloodstream culture met the eligibility criteria to be considered bacteremic. The majority of these patients (n = 24, 64.9%) presented vancomycin MIC ≥ 1.5 mg/mL, in opposite to 13 patients (35.1%) with MIC < 1.5 mg/mL. This study did not observe any statistical significative relationship between vancomycin MIC and treatment failure.

Vancomicina é o antimicrobiano de escolha no tratamento de bacteremias causadas por estafilococos resistentes à meticilina. No entanto, estudos recentes têm reportado que a vancomicina apresenta atividade reduzida contra Staphylococcus aureus resistentes à meticilina com concentrações inibitórias mínimas (CIMs) próximas do limite do ponto de corte de suscetibilidade, conforme critérios do CLSI, indicando falha terapêutica. Entretanto, existem poucos estudos à respeito dos Staphylococcus sp. coagulase negativa resistentes à meticilina (SCoNRM). Ademais, para determinação da CIM, deveria ser utilizado o método de referência microdiluição em caldo (MDC), mas a maioria dos laboratórios clínicos utiliza a técnica de Etest ou sistemas automatizados. Alguns estudos com S. aureus demonstraram discrepâncias entre MDC e Etest, contudo não existem dados referentes aos SCoN. Os objetivos deste estudo foram avaliar a correlação entre as CIMs de vancomicina determinadas pelas técnicas de MDC e Etest em 130 SCoNRM isolados de hemocultura, bem como verificar a relação entre valores de CIM e falha terapêutica entre pacientes com bacteremia por SCoNRM tratados com este antimicrobiano. A maioria dos resultados de CIM por MDC (98,5%) foram ≤1,0 mg/mL, enquanto o Etest apresentou 72,3% de CIM ≥ 1,5 mg/mL. As CIMs de vancomicina obtidas por Etest foram, em geral, uma a duas diluições maiores do que as CIMs obtidas por MDC. Os resultados indicam que a técnica de Etest gera valores de CIM consistentemente maiores do que os obtidos por MDC nos SCoNRM. Apenas 37 (28,5%) dos 130 pacientes com hemocultura positiva para SCoNRM apresentaram dados clínicos compatíveis com bacteremia. A maioria dos pacientes com bacteremia comprovada (n=24) apresentaram CIMs de vancomicina ≥1,5 mg/mL, sendo que 13 pacientes (35,1%) obtiveram CIM < 1,5 mg/mL. Este estudo não observou relação estatisticamente significativa entre valores de CIM de vancomicina que pudessem ser associados com falha terapêutica em pacientes com bacteremia por SCoNRM. / Vancomycin is the first-line therapy for methicillin-resistant staphylococci bacteremia. However, recent studies have reported that vancomycin demonstrates reduced activity against methicillin-resistant Staphylococcus aureus bacteremia, with vancomycin MICs at the high end of the CLSI susceptibility range indicating treatment failure. There is, however, little data considering methicillin-resistant coagulase-negative staphylococci (MRCoNS) bacteremia. Besides, the reference method that should be used for MIC determination is the broth microdilution (BMD), but many clinical laboratories use the commercial Etest technique or automated systems. Some reports have showed a growing number of vancomycin MIC discrepancies between BMD and Etest method for S. aureus, but there are no studies about CoNS. The aims of this study were to evaluated the correlation between the vancomycin MIC determined by the Etest and the BMD method for a total of 130 MRCoNS bloodstream isolates as well as to examine the relationship between vancomycin MICs and failure among patients with MRCoNS bacteremia treated with vancomycin. The vast majority (98.5%) of MIC results by BMD were ≤1.0 mg/mL in contrast to MIC by Etest which majority (72.3%) was ≥1.5 mg/mL. The vancomycin MICs obtained by the Etest for the same isolates were, in general, one to twofold higher than those obtained by the BMD method. The results indicate that the Etest provides vancomycin MIC values consistently higher than those obtained by BMD method for MRCoNS. Only 37 (28.5%) out of the 130 patients with a positive MRCoNS bloodstream culture met the eligibility criteria to be considered bacteremic. The majority of these patients (n = 24, 64.9%) presented vancomycin MIC ≥ 1.5 mg/mL, in opposite to 13 patients (35.1%) with MIC < 1.5 mg/mL. This study did not observe any statistical significative relationship between vancomycin MIC and treatment failure.

Magister Scientiae (Medical Bioscience) - MSc(MBS) / Staphylococcus aureus is a Gram-positive coccus belonging to the Stapylococcaeae family. S. aureus causes a wide range of infections that range from skin infections to lifethreatening infections such as pneumonia and endocarditis and is the major cause of hospital and community-acquired infections. Despite antibiotics being available for the treatment of S.aureus infections, resistance to a number of antibiotics has developed over the years due to their improper and continuous use. S. aureus develops resistance to various drugs via different mechanisms, one of which is the extrusion of the antibiotics through efflux pumps that play a role in its acquisition of multidrug resistance. The ability of methicillin-resistant S.aureus to develop resistance to a variety of antibiotics is causing global concern as treatment options are being limited. Various antimicrobial studies carried out on purified plant-based flavonoids have shown that flavonoids enhance the antibacterial effect of antibiotics. This study analysed antibacterial effects of the antibiotics; tetracycline, ampicillin, methicillin and vancomycin and three flavonoids; chrysin, naringenin and 7-hydroxyflavone, against methicillin-sensitive ATCC 25923 (MSSA) and methicillin-resistant ATCC 33591 (MRSA) S. aureus strains, using the Kirby-Bauer disk diffusion and microtitre microdilution assays. In the Kirby- Bauer assay, the antibiotics demonstrated inhibitory effects on the growth of MSSA ATCC 25923. However MRSA ATCC 33591 was only susceptible to vancomycin, with minimal inhibition zones observed with ampicillin. The flavonoids did not enhance or reduce the antibacterial activities of the antibiotics as the zones of inhibition sizes remained unchanged in the combination studies. Microtitre assay results revealed that naringenin enhanced the antibacterial activities of the antibiotics tetracycline and ampicillin, against MSSA ATCC 25923 and MRSA 33591. This was evident as calculated synergistic ratios by the Abbot formula showed that naringenin had an additive effect. The presence of the efflux pump genes in MSSA ATCC 25923 and MRSA ATCC 33591 was compared using polymerase chain reaction (PCR). The mepA and gyrA genes were identified in both strains whereas sepA was identified in MRSA ATCC 33591. The presence of efflux pump genes in both MSSA ATCC 25923 and MRSA ATCC 33591 also confirmed that the presence or absence of the genes may contribute to antibiotic resistance. The presence of sepA in the MRSA and not the MSSA confirmed that this gene plays a role in conferring drug resistance.

Bacterial infections remain a significant threat to human health. Due to the emergence of widespread antibiotic resistance, development of novel antibiotics is required in order to ensure that effective treatment remains available. The aim of this study was to isolate and identify the fraction responsible for the antimicrobial activity in Tabernaemontana elegans (Stapf.) root extracts. The active fraction was characterised by thin layer chromatography (TLC) and gas chromatography – mass spectrometry (GC-MS). Antibacterial activity was determined using the broth micro-dilution assay and antimycobacterial activity using the BACTEC radiometric assay. Cytotoxicity of the crude extract and fractions was assessed against primary cell cultures; lymphocytes and fibroblasts; as well as a hepatocarcinoma (HepG2) and macrophage (THP-1) cell line using the Neutral Red uptake and MTT assays. The crude root extracts were found to contain a high concentration of alkaloids (1.2% w/w). GC-MS analysis identified the indole alkaloids, voacangine and dregamine, as major components. Antibacterial activity was limited to the Gram-positive bacteria and Mycobacterium species, with MIC values in the range of 64 – 256 ìg/ml. When combined with antibiotics, additive antibacterial effects were observed. Marked cytotoxicity to all cell lines tested was evident in the MTT and Neutral Red uptake assays, with IC50 values ranging between 1.11 – 9.81 ìg/ml. This study confirms the antibacterial activity of T. elegans and supports its potential for being investigated further for the development of a novel antibacterial compound. / Dissertation (MSc)--University of Pretoria, 2011. / Pharmacology / unrestricted

No description available.

>Magister Scientiae - MSc / The growing resistance of Methicillin-Resistant Staphylococcus aureus (MRSA) to currently prescribed drugs has resulted in the failure of prevention and treatment of different infections caused by the superbug. Therefore, to keep pace with the resistance, there is a pressing need for novel antimicrobial agents, especially from non-conventional sources. Several natural products (NPs) have displayed varying in vitro activities against the pathogen but few of these natural compounds have been studied for their prospects to be potential antimicrobial drug candidates. This may be due to the high cost, tedious, and time-consuming process of conducting the important preclinical tests on these compounds. Hence, there is a need for cost-effective strategies for mining the available data on these natural compounds. This would help to get the knowledge that may guide rational prioritization of “likely to succeed” natural compounds to be developed into potential antimicrobial drug candidates. Cheminformatic approaches in drug discovery enable chemical data mining, in conjunction with unsupervised and supervised learning from available bioactivity data that may unlock the full potential of NPs in antimicrobial drug discovery. Therefore, taking advantage of the available NPs with their known in vitro activity against MRSA, this study conducted cheminformatic and data mining analysis towards hit profiling, hit-prioritization, hit-optimization, and target prediction of anti-MRSA NPs. Cheminformatic profiling was conducted on the 111 anti-MRSA NPs (AMNPs) retrieved from literature. About 20 current drugs for MRSA (CDs) were used as a reference to identify AMNPs with promising prospects to become drug candidates.

Background: Increasingly frequent reports of vancomycin treatment failures for serious methicillin-resistant Staphylococcus aureus (MRSA) infections provide impetus for comparative in vitro studies to assess the activity of newer antimicrobial agents against a range of MRSA isolates. Methods: A sample of 168 MRSA derived from a long-term MRSA collection was subjected to susceptibility testing to telavancin, daptomycin, linezolid, tigecycline and vancomycin by broth micro-dilution. Data were reviewed for sporadic occurrence of isolates with reduced susceptibility. Analyses were performed to test for temporal trends toward decreasing susceptibility and to compare susceptibility of isolates from different infection sites. Results: No MRSA isolate from any time period was resistant to test antibiotics. For daptomycin, linezolid and tigecycline, there were no susceptibility differences between the pre- and postclinical availability periods. All newer agents here active against MRSA isolates with minimum inhibitory concentrations (MICs) of vancomycin >1 mg/l, but there were significant correlations in susceptibility among several pairs of antibiotics. Conclusions: Telavancin and other newer antistaphylococcal agents were fully active against MRSA from various infection sites including isolates with vancomycin MIC >1 mg/l.

What is known and objective: Treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is a long-standing challenge to health care, often complicated by metastatic infections, treatment failure and mortality. When MRSA bacteraemia persists despite adequate initial treatment, current Infectious Diseases Society of America guidelines recommend evaluation and removal of possible sources of infection. In addition, a change in therapy may be considered. The objective of this review was to explore the therapeutic options for the treatment of persistent MRSA bacteraemia. Methods: A literature search of PubMed, MEDLINE and Google Scholar was performed using the following search terms: [methicillin-resistant Staphylococcus aureus OR MRSA] AND [bacteraemia OR bloodstream infection] AND [persistent OR persistence OR refractory OR treatment failure OR salvage] AND treatment. We evaluated relevant, adult, English-language, peer-reviewed studies published between 1985 and May 2018. In vitro and animal studies were considered as supportive of in vivo data. Results and discussion: Randomized, controlled trials are lacking. However, case series and case reports support multiple treatment options including high-dose daptomycin in combination with an antistaphylococcal β-lactam, ceftaroline, trimethoprim-sulfamethoxazole (TMP-SMX) or fosfomycin; ceftaroline alone or in combination with vancomycin or TMP-SMX; linezolid alone or in combination with a carbapenem, or telavancin. What is new and conclusion: Given the heterogeneity of the data, a preferred regimen has not emerged. Prescribers must take into consideration recent exposure, source control, and available synergy and clinical data. Further comparative trials are needed to establish a preferred regimen and the creation of a universal treatment algorithm.